Tesamorelin vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Egrifta, TH9507
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. One of the few peptides with FDA approval.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
A long-acting GHRH analog with Drug Affinity Complex for extended half-life. Provides sustained GH elevation for days with single injection.
Key Comparison Insights
- Tesamorelin is FDA approved, while CJC-1295 DAC remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to CJC-1295 DAC (Human Trials).
Detailed Comparison
| Attribute | Tesamorelin | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. | CJC-1295 DAC contains a reactive linker that binds to albumin after injection. This extends half-life from minutes to 6-8 days, providing sustained GHRH stimulation and GH/IGF-1 elevation. |
| Common Dosing | 2 mg daily Once daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | Indefinite for approved indication | 8-12 weeks typical |
| Best Time to Take | Before bed (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | FDA approved based on trials showing significant reduction in trunk fat (up to 18%) in HIV lipodystrophy patients. Studies also show improvements in lipid profiles, particularly triglycerides. Research ongoing for cognitive benefits and NAFLD treatment. | Studies show sustained 2-10 fold increase in GH levels lasting several days. Single weekly injection maintains elevated IGF-1. Less physiologic than pulsatile protocols but more convenient. |
Frequently Asked Questions: Tesamorelin vs CJC-1295 DAC
What is the difference between Tesamorelin and CJC-1295 DAC?
Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. one of the few peptides with fda approval. CJC-1295 DAC is a growth hormone peptide that a long-acting ghrh analog with drug affinity complex for extended half-life. provides sustained gh elevation for days with single injection. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Tesamorelin or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. Tesamorelin is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Tesamorelin and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Tesamorelin and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Tesamorelin and CJC-1295 DAC is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.